文献速递心脑血管急症

老年急性缺血性脑卒中患者血清miR-24与miR-29b的表达及其神经功能预后评估价值

[Expressions and neural function prognostic evaluation of serum microRNA-24 and microRNA-29b in elderly patients with acute ischemic stroke].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论老年AIS患者血清miR-24、miR-29b表达下调,与神经功能缺损程度及预后相关;两指标联合预测预后不良的AUC为0.920。

该前瞻性研究纳入2017年1月1日至2019年3月31日儋州市人民医院神经内科收治的170例老年急性缺血性脑卒中患者,按mRS评分分为预后良好组(mRS≤2,n=105)与预后不良组(mRS>2,n=65),并按NIHSS评分分为轻度组(NIHSS<5,n=50)、中度组(NIHSS 5-20,n=76)和重度组(NIHSS>20,n=44),另设65例健康对照。采用RT-qPCR测定血清miR-24和miR-29b表达。结果显示AIS组两指标均显著低于健康对照组,预后不良组显著低于预后良好组,重度组显著低于轻、中度组。ROC分析显示两指标联合预测预后不良的AUC为0.920(95%CI 0.861-0.982),高于miR-24单独(AUC 0.802)或miR-29b单独(AUC 0.835)。结论认为两指标下调与神经功能缺损程度及预后相关,联合检测对预后评估有一定价值。

要点

  • 老年AIS患者血清miR-24(2-ΔΔCt:0.64±0.17 vs 2.18±0.85)和miR-29b(0.72±0.21 vs 3.05±0.96)均显著低于健康对照(均P<0.01)。
  • 预后不良组(mRS>2)miR-24(0.20±0.05 vs 1.16±0.48)和miR-29b(0.18±0.03 vs 1.41±0.56)均显著低于预后良好组(mRS≤2)(均P<0.01)。
  • 重度组(NIHSS>20)两指标显著低于轻、中度组,中度组又显著低于轻度组(均P<0.01)。
  • miR-24预测预后不良的最佳截断值为0.53,miR-29b为0.48;两者联合AUC 0.920(95%CI 0.861-0.982),灵敏度92.0%、特异度85.7%。
  • 血清miR-24、miR-29b与NIHSS评分(r=-0.758、-0.794)及mRS评分(r=-0.817、-0.860)均呈负相关(均P<0.01)。

适用人群与场景

  • 2017年1月1日至2019年3月31日儋州市人民医院神经内科收治的老年急性缺血性脑卒中患者170例。
  • 健康对照组为同期65例健康志愿者。

诊断标准与关键阈值

  • 神经功能预后分组采用改良Rankin量表(mRS)评分:mRS≤2分为预后良好组(n=105),mRS>2分为预后不良组(n=65)。
  • 神经功能缺损程度分组采用美国国立卫生研究院卒中量表(NIHSS)评分:NIHSS<5分为轻度组(n=50),NIHSS 5-20分为中度组(n=76),NIHSS>20分为重度组(n=44)。
  • 血清miR-24预测老年AIS患者神经功能预后不良的最佳截断值为0.53,miR-29b为0.48。

研究设计与关键结果

  • 研究类型为前瞻性研究,纳入老年AIS患者170例及健康对照65例,采用实时荧光定量逆转录聚合酶链反应(RT-qPCR)测定血清miR-24和miR-29b表达。
  • AIS组血清miR-24(2-ΔΔCt:0.64±0.17 vs 2.18±0.85)和miR-29b(0.72±0.21 vs 3.05±0.96)均显著低于健康对照组(均P<0.01)。
  • 预后不良组血清miR-24(0.20±0.05 vs 1.16±0.48)和miR-29b(0.18±0.03 vs 1.41±0.56)均显著低于预后良好组(均P<0.01)。
  • 重度组血清miR-24(0.13±0.02 vs 1.30±0.51、0.56±0.14)和miR-29b(0.09±0.01 vs 1.52±0.60、0.62±0.13)均显著低于轻度组和中度组(均P<0.01),中度组又显著低于轻度组(均P<0.01)。
  • ROC曲线分析:miR-24单独预测预后不良的AUC为0.802(95%CI 0.742-0.860),miR-29b单独为0.835(95%CI 0.778-0.890),两者联合为0.920(95%CI 0.861-0.982),联合预测显著高于单独miR-24(Z=6.513)和单独miR-29b(Z=4.902)(均P<0.05),联合预测的灵敏度和特异度分别为92.0%和85.7%。
  • Pearson相关分析:血清miR-24、miR-29b与NIHSS评分呈负相关(r分别为-0.758、-0.794),与mRS评分呈负相关(r分别为-0.817、-0.860)(均P<0.01)。

证据类型、等级与局限

  • 证据类型:前瞻性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,血清miR-24和miR-29b表达下调与老年AIS患者神经功能缺损程度及神经功能预后相关,两者联合对预测老年AIS患者神经功能预后有一定价值。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the expressions of serum microRNA-24 (miR-24) and microRNA-29b (miR-29b) in elderly patients with acute ischemic stroke (AIS) and their neural function prognostic value.

METHODS: A prospective study was conducted. 170 elderly patients with AIS admitted to department of neurology of Danzhou People's Hospital from January 1st, 2017 to March 31st, 2019 were enrolled. According to modified Rankin scale (mRS) score, the patients were divided into good neural function prognosis group (mRS score ≤ 2, n = 105) and poor neural function prognosis group (mRS score > 2, n = 65). According to National Institutes of Health stroke scale (NIHSS) score, the patients were divided into mild group (NIHSS score < 5, n = 50), moderate group (NIHSS score 5-20, n = 76) and severe group (NIHSS score > 20, n = 44). Sixty-five healthy volunteers in the same period were enrolled as the control group. The expressions of serum miR-24 and miR-29b were determined by real-time fluorescent quantitative reverse transcription-polymerase chain reaction (RT-qPCR). Receiver operating characteristic (ROC) curve was plotted to analyze the value of serum expressions of miR-24 and miR-29b for predicting the poor neural function prognosis of elderly patients with AIS. Pearson correlation was used to analyze the correlation between the expressions of serum miR-24, miR-29b and NIHSS, mRS scores in elderly patients with AIS.

RESULTS: The expressions of serum miR-24 and miR-29b in the AIS group were significantly lower than those in the healthy control group [miR-24 (2-ΔΔCt): 0.64±0.17 vs. 2.18±0.85, miR-29b (2-ΔΔCt): 0.72±0.21 vs. 3.05±0.96, both P < 0.01]. The expressions of serum miR-24 and miR-29b in the poor neural function prognosis group were significantly lower than those in the good neural function prognosis group [miR-24 (2-ΔΔCt): 0.20±0.05 vs. 1.16±0.48, miR-29b (2-ΔΔCt): 0.18±0.03 vs. 1.41±0.56, both P < 0.01]. The expressions of serum miR-24 and miR-29b in the severe group were significantly lower than those in the mild and moderate groups [miR-24 (2-ΔΔCt): 0.13±0.02 vs. 1.30±0.51, 0.56±0.14; miR-29b (2-ΔΔCt): 0.09±0.01 vs. 1.52±0.60, 0.62±0.13; all P < 0.01], and they were significantly lower in the moderate group than those in the mild group (all P < 0.01). ROC curve analysis showed that the optimal cut-off values of serum miR-24 and miR-29b expressions for predicting poor neural function prognosis in elderly AIS patients were 0.53 and 0.48, respectively. The area under ROC curve (AUC) of the two combined prognoses was 0.920 [95% confidence interval (95%CI) was 0.861-0.982], and it was significantly higher than that of miR-24 (AUC was 0.802, 95%CI was 0.742-0.860) or miR-29b (AUC was 0.835, 95%CI was 0.778-0.890) alone (Z values were 6.513 and 4.902, respectively, both P < 0.05), with sensitivity and specificity of 92.0% and 85.7%. Pearson correlation analysis showed that the expressions of serum miR-24 and miR-29b were negatively correlated with NIHSS score (r values were -0.758 and -0.794, respectively) and mRS score (r values were -0.817 and -0.860, respectively) in elderly AIS patients (all P < 0.01).

CONCLUSIONS: The down-regulated expressions of serum miR-24 and miR-29b are correlated with the severity degree of neurological impairment and neural function prognosis of elderly AIS patients, and the two combined have certain value for predicting the neural function prognosis of elderly AIS patients.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Guo C, Zhong C, Li Q, et al. [Expressions and neural function prognostic evaluation of serum microRNA-24 and microRNA-29b in elderly patients with acute ischemic stroke]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32148236. doi:10.3760/cma.j.cn121430-20190715-00014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。